Celanese Q3 sales rise 6%

By Reuters News


Overview

  • US chemical maker's Q3 net sales rose 6% yr/yr but missed analyst expectations

  • Adjusted EPS for Q3 beat consensus, supported by strategic growth and commercial execution

  • Company generated strong Q3 free cash flow and advanced deleveraging efforts


Outlook

  • Celanese raises full-year 2026 adj EPS outlook to $6.00-$6.25

  • Company increases 2026 free cash flow forecast to $750-$800 mln

  • Celanese expects year-end seasonal moderation across both businesses in Q4


Result Drivers

  • STRATEGIC GROWTH INITIATIVES - Co said progress on strategic growth initiatives and commercial actions across the portfolio drove yr/yr net sales growth

  • ENGINEERED MATERIALS MIX - Growth in medical and electronics applications supported favorable product mix and earnings improvement in Engineered Materials segment

  • ACETYL CHAIN PRICING - Acetyl Chain segment benefited from pricing favorability and incremental spot opportunities, offsetting modest demand softness


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$2.56 bln

$2.62 bln (14 Analysts)

Q3 Adjusted EPS

Beat

$1.65

$1.56 (18 Analysts)

Q3 Net Earnings

$78 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the specialty chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Celanese Corp is $59.00, about 19.7% above its October 30 closing price of $49.30

  • The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 7 three months ago


Reuters Recommended Reads

  • Nov 2 - Allison Transmission Q3 sales jump 121%, beat estimates

  • Nov 2 - Diamondback Energy Q3 revenue beats on higher oil output

  • Nov 2 - Marriott tops Q3 revenue, profit estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.